MWNA
NBRV

Marshall Wace North America’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Marshall Wace North America’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,508
Closed -$1.9M – 1852
2018
Q1 		$1.9M Sell
1,508
-855
-36% -$1.26M 0.01% 819
2017
Q4 		$3.53M Sell
2,363
-221
-9% -$349K 0.02% 678
2017
Q3 		$5.17M Buy
+2,584
New +$6.06M 0.03% 537

Other funds holding NBRV

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return

Marshall Wace North America's NBRV Position: Q2 2018 in Review

Marshall Wace North America sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2018, closing a stake of 1,508 shares — an estimated $1.9M sold.

Marshall Wace North America first reported a position in NBRV in Q3 2017 and held it in 3 quarters. The position peaked at $5.17M in Q3 2017. 42 funds tracked by Wall St. Rank hold NBRV as of Q2 2018.

  • Marshall Wace North America reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2018 after selling out during the quarter.
  • Marshall Wace North America sold 1,508 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2018, an estimated $1.9M.
  • Marshall Wace North America first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 3 quarters.
  • Marshall Wace North America's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $5.17M in Q3 2017.
  • 42 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2018.

Based on Marshall Wace North America's 13F filing for Q2 2018, filed 14 Aug 2018.